{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:31:17Z","timestamp":1740133877709,"version":"3.37.3"},"reference-count":35,"publisher":"BMJ","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["75N94021P00910"],"award-info":[{"award-number":["75N94021P00910"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Sex Transm Infect"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Continued high incidence of HIV and other STIs, paired with rising antibiotic resistance to a number of existing treatments, warrants the development of new pharmaceutical approaches for STI prevention. Multipurpose prevention technologies (MPTs) offer an innovative approach for expanding HIV\/STI prevention. The majority of MPT product candidates currently in development include HIV prevention, while only half include compounds active against non-HIV STIs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This narrative review focuses on compounds in preclinical development (in vitro and in vivo) through phase 3 clinical trials with activity against one or more of the following infections: HIV, HSV-1, HSV-2<jats:italic>, Chlamydia trachomatis<\/jats:italic>,<jats:italic>Neisseria gonorrhoeae<\/jats:italic>,<jats:italic>Treponema pallidum<\/jats:italic>, and<jats:italic>Trichomonas vaginalis.<\/jats:italic>Bacterial vaginosis is included due to its association with increased risk of STIs. The focus is on compounds with novel mechanisms of action and prophylactic and\/or therapeutic potential. Articles published in PubMed between 2011 and 2021, NIH RePorter and conference abstracts and proceedings between 2020 and 2021 were searched. Excluded from the review are compounds that are already being used in MPT product candidates.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main results<\/jats:title><jats:p>There is a growing pipeline of compounds targeting viral STIs, many of which have successfully transitioned from preclinical to clinical stages of development. However, the product development pipeline remains limited for compounds that target bacterial STIs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The paucity of new pharmaceutical approaches for STI prevention, particularly non-HIV STIs, remains a public health gap. Future funding priorities should include STI prevention research. Despite limited attention to STI prevention in the development of MPTs, many research institutions worldwide are working on discoveries of new compounds, exploring new indications for existing drugs or on innovative drug delivery mechanisms. Our findings can be used to connect researchers across the globe to advance the development of compounds that have potential as active pharmaceutical ingredients in future MPTs.<\/jats:p><\/jats:sec>","DOI":"10.1136\/sextrans-2022-055647","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T10:22:36Z","timestamp":1678962156000},"page":"sextrans-2022-055647","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Expanding the pipeline for multipurpose prevention technologies: compounds with potential activity to prevent or treat HIV and other STIs"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7521-7085","authenticated-orcid":false,"given":"Bethany","family":"Young Holt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anke","family":"Hemmerling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,3,6]]},"reference":[{"unstructured":"UNAIDS . In danger: UNAIDS global AIDS update 2022. 2022. Available: https:\/\/www.unaids.org\/en\/resources\/documents\/2022\/in-danger-global-aids-update","key":"2023031603202325000_sextrans-2022-055647v1.1"},{"unstructured":"World Health Organization . Sexually transmitted infections (STIs). 2022. Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/sexually-transmitted-infections-(stis)","key":"2023031603202325000_sextrans-2022-055647v1.2"},{"doi-asserted-by":"crossref","unstructured":"Mwatelah R , McKinnon LR , Baxter C , et al . Mechanisms of sexually transmitted infection-induced inflammation in women: implications for HIV risk. J Int AIDS Soc 2019;22 Suppl 6:e25346. doi:10.1002\/jia2.25346","key":"2023031603202325000_sextrans-2022-055647v1.3","DOI":"10.1002\/jia2.25346"},{"doi-asserted-by":"publisher","key":"2023031603202325000_sextrans-2022-055647v1.4","DOI":"10.1097\/COH.0000000000000232"},{"unstructured":"Centers for Disease Control and Prevention . STDs and HIV \u2013 CDC basic fact sheet. 2022. Available: https:\/\/www.cdc.gov\/std\/hiv\/stdfact-std-hiv.htm","key":"2023031603202325000_sextrans-2022-055647v1.5"},{"unstructured":"Centers for Disease Control and Prevention . Drug-resistant gonorrhea. 2022. Available: https:\/\/www.cdc.gov\/std\/gonorrhea\/arg\/default.htm","key":"2023031603202325000_sextrans-2022-055647v1.6"},{"unstructured":"World Health Organization . High rates of unintended pregnancies linked to gaps in family planning services: new WHO study. 2022. Available: https:\/\/www.who.int\/news\/item\/25-10-2019-high-rates-of-unintended-pregnancies-linked-to-gaps-in-family-planning-services-new-who-study","key":"2023031603202325000_sextrans-2022-055647v1.7"},{"unstructured":"The Initiative for MPTs . MPT product development database. 2022. Available: mpts101.org","key":"2023031603202325000_sextrans-2022-055647v1.8"},{"unstructured":"The Initiative for MPTs . Compounds with potential activity to prevent or treat HIV and other sexually transmitted infections: A landscape review. The IMPT, 2022. Available: https:\/\/theimpt.org\/compounds-with-potential-activity-to-preventor-treat-hiv-and-other-sexually-transmitted-infections-a-landscape-review\/","key":"2023031603202325000_sextrans-2022-055647v1.9"},{"key":"2023031603202325000_sextrans-2022-055647v1.10","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/biolre\/ioaa092","article-title":"Towards a roadmap to advance non-hormonal contraceptive multipurpose prevention technologies: strategic insights from key stakeholders\u2020","volume":"103","author":"Hemmerling","year":"2020","journal-title":"Biol Reprod"},{"key":"2023031603202325000_sextrans-2022-055647v1.11","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1080\/13625187.2018.1508650","article-title":"A strategic action framework for multipurpose prevention technologies combining contraceptive hormones and antiretroviral drugs to prevent pregnancy and HIV","volume":"23","author":"Young Holt","year":"2018","journal-title":"Eur J Contracept Reprod Health Care"},{"doi-asserted-by":"publisher","key":"2023031603202325000_sextrans-2022-055647v1.12","DOI":"10.1016\/j.biopha.2018.11.127"},{"doi-asserted-by":"publisher","key":"2023031603202325000_sextrans-2022-055647v1.13","DOI":"10.1038\/nrd1468"},{"doi-asserted-by":"publisher","key":"2023031603202325000_sextrans-2022-055647v1.14","DOI":"10.1093\/infdis\/jis298"},{"doi-asserted-by":"publisher","key":"2023031603202325000_sextrans-2022-055647v1.15","DOI":"10.1093\/cid\/civ298"},{"doi-asserted-by":"publisher","key":"2023031603202325000_sextrans-2022-055647v1.16","DOI":"10.1097\/00002030-199301000-00015"},{"doi-asserted-by":"publisher","key":"2023031603202325000_sextrans-2022-055647v1.17","DOI":"10.1097\/00002030-199813000-00019"},{"doi-asserted-by":"publisher","key":"2023031603202325000_sextrans-2022-055647v1.18","DOI":"10.1056\/NEJMoa2031738"},{"unstructured":"World Health Organization . Key facts HIV. WHO, 2022. Available: https:\/\/cdn.who.int\/media\/docs\/default-source\/hq-hiv-hepatitis-and-stis-library\/key-facts-hiv-2021-26july2022.pdf?sfvrsn=8f4e7c93_5","key":"2023031603202325000_sextrans-2022-055647v1.19"},{"unstructured":"World Health Organization . WHO guidelines for the treatment of neisseria gonorrhoeae (WHO guidelines approved by the guidelines review committee). Geneva: World Health Organization, 2016. Available: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK379221\/","key":"2023031603202325000_sextrans-2022-055647v1.20"},{"key":"2023031603202325000_sextrans-2022-055647v1.21","doi-asserted-by":"crossref","first-page":"860442","DOI":"10.3389\/fcimb.2022.860442","article-title":"An overview of mucosa-associated protozoa: challenges in chemotherapy and future perspectives","volume":"12","author":"Santos","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"doi-asserted-by":"publisher","key":"2023031603202325000_sextrans-2022-055647v1.22","DOI":"10.1016\/0002-9378(88)90078-6"},{"doi-asserted-by":"publisher","key":"2023031603202325000_sextrans-2022-055647v1.23","DOI":"10.1177\/0956462415616038"},{"doi-asserted-by":"publisher","key":"2023031603202325000_sextrans-2022-055647v1.24","DOI":"10.1097\/01.AOG.0000247627.84791.91"},{"doi-asserted-by":"publisher","key":"2023031603202325000_sextrans-2022-055647v1.25","DOI":"10.1086\/503780"},{"unstructured":"Infectious Diseases Society of America . Antibiotic development: the 10 x \u201920 initiative. 2022. Available: https:\/\/www.idsociety.org\/policy--advocacy\/antimicrobial-resistance\/antibiotic-development-the-10-x-20-initiative\/","key":"2023031603202325000_sextrans-2022-055647v1.26"},{"unstructured":"World Health Organization . Congenital syphilis - mother-to-child transmission of syphilis. 2022. Available: https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/stis\/prevention\/mother-to-child-transmission-of-syphilis","key":"2023031603202325000_sextrans-2022-055647v1.27"},{"unstructured":"World Health Organization . Herpes simplex virus. 2022. Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/herpes-simplex-virus","key":"2023031603202325000_sextrans-2022-055647v1.28"},{"doi-asserted-by":"crossref","unstructured":"Huai P , Li F , Li Z , et al . Prevalence, risk factors, and medical costs of Chlamydia trachomatis infections in Shandong Province, China: a population-based, cross-sectional study. BMC Infect Dis 2018;18:534. doi:10.1186\/s12879-018-3432-y","key":"2023031603202325000_sextrans-2022-055647v1.29","DOI":"10.1186\/s12879-018-3432-y"},{"doi-asserted-by":"publisher","key":"2023031603202325000_sextrans-2022-055647v1.30","DOI":"10.1016\/S1473-3099(16)30092-5"},{"unstructured":"Centers for Disease Control and Prevention . STI treatment guidelines. Centers for Disease Control and Prevention, 2021. Available: https:\/\/www.cdc.gov\/std\/treatment-guidelines\/default.htm","key":"2023031603202325000_sextrans-2022-055647v1.31"},{"unstructured":"Centers for Disease Control and Prevention . National overview - sexually transmitted disease surveillance, 2019. 2022. Available: https:\/\/www.cdc.gov\/std\/statistics\/2019\/overview.htm","key":"2023031603202325000_sextrans-2022-055647v1.32"},{"unstructured":"Centers for Disease Control and Prevention . CDC \u2013 syphilis treatment. 2022. Available: https:\/\/www.cdc.gov\/std\/syphilis\/treatment.htm","key":"2023031603202325000_sextrans-2022-055647v1.33"},{"unstructured":"World Health Organization . WHO publishes new estimate on congenital syphilis. 2019. Available: https:\/\/www.who.int\/news\/item\/26-02-2019-who-publishes-new-estimates-on-congenital-syphilis","key":"2023031603202325000_sextrans-2022-055647v1.34"},{"key":"2023031603202325000_sextrans-2022-055647v1.35","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.placenta.2019.03.011","article-title":"The influence of the vaginal microbiota on preterm birth: a systematic review and recommendations for a minimum dataset for future research","volume":"79","author":"Peelen","year":"2019","journal-title":"Placenta"}],"container-title":["Sexually Transmitted Infections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/sextrans-2022-055647","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T10:22:49Z","timestamp":1678962169000},"score":1,"resource":{"primary":{"URL":"https:\/\/sti.bmj.com\/lookup\/doi\/10.1136\/sextrans-2022-055647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,6]]},"references-count":35,"alternative-id":["10.1136\/sextrans-2022-055647"],"URL":"https:\/\/doi.org\/10.1136\/sextrans-2022-055647","relation":{},"ISSN":["1368-4973","1472-3263"],"issn-type":[{"type":"print","value":"1368-4973"},{"type":"electronic","value":"1472-3263"}],"subject":[],"published":{"date-parts":[[2023,3,6]]}}}